Puma Biotechnology
Open
$7.30
Prev. Close
$7.30
High
$7.33
Low
$7.30
Market Snapshot
$372.92M
15.3
0.61
$230.47M
179
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 179 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 179 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.
Recently from Cashu
Dick’s Sporting Goods Adjusts Strategy and Guidance After Foot Locker Acquisition Challenges
Navigating Challenges in Retail: Dick's Sporting Goods' Strategic Pivot After Foot Locker Acquisition In the current retail landscape, Dick's Sporting Goods faces notable challenges following its acqu…
Puma Biotechnology Navigates Regulatory Challenges Amid Industry Consolidation and Merger Dynamics
Puma Biotechnology Faces Regulatory Scrutiny Amid Industry Consolidation Puma Biotechnology, a company focused on the commercialization and development of innovative cancer therapies, operates within…
Adidas Struggles with Revenue Forecasts Amid Market Changes; Puma Biotechnology Focuses on Cancer Therapies
Adidas Faces Revenue Concerns Amid Shift in Market Dynamics Adidas experiences significant challenges as it announces a disappointing revenue outlook for 2026, projecting only high single-digit growth…
Adidas Growth Challenges Impact Industry, Including Puma's Profitability Amid Market Turbulence
Adidas Faces Growth Challenges Amid Market Turbulence, Impacting Industry Peers Adidas experiences significant turbulence as it reveals a disappointing revenue outlook for 2026, forecasting high singl…